Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.60 -0.08 (-0.51%)
Streaming Delayed Price Updated: 10:11 AM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 239,113
Open 15.87
Bid (Size) 15.60 (500)
Ask (Size) 15.64 (500)
Prev. Close 15.68
Today's Range 15.57 - 15.98
52wk Range 6.550 - 16.20
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Passes Louis Navellier's Strict Growth Stock Screen
Aurinia Pharmaceuticals (AUPH) exemplifies a top growth stock, showing explosive earnings growth, soaring cash flow, and consistent earnings surprises. 
Via Chartmill
Earnings Scheduled For November 4, 2025
 
Via Benzinga

Performance

YTD
+77.9%
+77.9%
1 Month
+40.5%
+40.5%
3 Month
+37.8%
+37.8%
6 Month
+99.5%
+99.5%
1 Year
+83.7%
+83.7%

More News

Read More
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
A Peek at Aurinia Pharmaceuticals's Future Earnings
Via Benzinga
FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse
Via Benzinga
Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery
Via Stocktwits
Earnings Scheduled For July 31, 2025
Via Benzinga
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’
Via Stocktwits
Topics Lawsuit
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Traits in Fundamental Analysis
Via Chartmill
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Responds to Now Retracted LinkedIn Post
From Aurinia Pharmaceuticals Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Louis Navellier's Growth Screen
Via Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
Via Investor's Business Daily
Topics ETFs
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Metrics and Earnings Momentum
Via Chartmill
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Via Investor's Business Daily
Topics ETFs
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Fits Louis Navellier’s High-Growth Stock Criteria
Via Chartmill
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
Via Investor's Business Daily
Aurinia (AUPH) Q2 Revenue Jumps 22%
Via The Motley Fool
Topics Intellectual Property
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Via Chartmill
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Via Chartmill
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Frequently Asked Questions

Is Aurinia Pharmaceuticals Inc - Common Shares publicly traded?
Yes, Aurinia Pharmaceuticals Inc - Common Shares is publicly traded.
What exchange does Aurinia Pharmaceuticals Inc - Common Shares trade on?
Aurinia Pharmaceuticals Inc - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares?
The ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares is AUPH on the Nasdaq Stock Market
What is the current price of Aurinia Pharmaceuticals Inc - Common Shares?
The current price of Aurinia Pharmaceuticals Inc - Common Shares is 15.60
When was Aurinia Pharmaceuticals Inc - Common Shares last traded?
The last trade of Aurinia Pharmaceuticals Inc - Common Shares was at 11/12/25 10:11 AM ET
What is the market capitalization of Aurinia Pharmaceuticals Inc - Common Shares?
The market capitalization of Aurinia Pharmaceuticals Inc - Common Shares is 2.00B
How many shares of Aurinia Pharmaceuticals Inc - Common Shares are outstanding?
Aurinia Pharmaceuticals Inc - Common Shares has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.